NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT06908993 2025-12-17
COMET
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT05782361 2025-08-20
POTENT
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT05120960 2024-04-17
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05439993 2022-07-05
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
Phase 1/2 Recruiting
NCT04647838 2020-12-02
Tepotinib in Solid Tumors Harboring MET Alterations
Chungbuk National University Hospital
Phase 2 Unknown